FDA approves pancreatic cancer drug that doubles patient survival

The US Food and Drug Administration has granted accelerated approval to a new oral drug for pancreatic cancer. The therapy can double the survival time of patients with advanced-stage disease. Doctors are calling the approval a breakthrough in oncology.